Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Phenotype and Genotype Heterogeneity of Pla2g6-Associated Neurodegeneration in a Cohort of Pediatric and Adult Patients Publisher Pubmed



Dehnavi AZ1 ; Bemanalizadeh M1, 2 ; Kahani SM3 ; Ashrafi MR1 ; Rohani M4, 5 ; Toosi MB6, 7 ; Heidari M1 ; Hosseinpour S1 ; Amini B1 ; Zokaei S8, 9 ; Rezaei Z1 ; Aryan H8, 10 ; Amanat M11 ; Vahidnezhad H12, 13 Show All Authors
Authors
  1. Dehnavi AZ1
  2. Bemanalizadeh M1, 2
  3. Kahani SM3
  4. Ashrafi MR1
  5. Rohani M4, 5
  6. Toosi MB6, 7
  7. Heidari M1
  8. Hosseinpour S1
  9. Amini B1
  10. Zokaei S8, 9
  11. Rezaei Z1
  12. Aryan H8, 10
  13. Amanat M11
  14. Vahidnezhad H12, 13
  15. Mohammadi P3, 14
  16. Garshasbi M3
  17. Tavasoli AR1, 12, 14
Show Affiliations
Authors Affiliations
  1. 1. Department of Pediatrics, Division of Pediatric Neurology, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Faculty of Medical Sciences, Department of Medical Genetics, Tarbiat Modares University, Tehran, Iran
  4. 4. Skull Base Research Center, The Five Senses Health Institute, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Neurology, Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pediatrics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  8. 8. Dr. Farhud’s Genetic Clinic, Tehran, Iran
  9. 9. School of Advanced Medical Science, Islamic Azad University, Tehran, Iran
  10. 10. National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
  11. 11. Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, United States
  12. 12. Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States
  13. 13. Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States
  14. 14. Pediatric Neurology Division, Children’s Medical Center, Pediatrics Center of Excellence, Ataxia Clinic, Tehran University of Medical Sciences, Tehran, Iran

Source: Orphanet Journal of Rare Diseases Published:2023


Abstract

Background: Phospholipase-associated neurodegeneration (PLAN) caused by mutations in the PLA2G6 gene is a rare neurodegenerative disorder that presents with four sub-groups. Infantile neuroaxonal dystrophy (INAD) and PLA2G6-related dystonia-parkinsonism are the main two subtypes. In this cohort, we reviewed clinical, imaging, and genetic features of 25 adult and pediatric patients harboring variants in the PLA2G6. Methods: An extensive review of the patients’ data was carried out. Infantile Neuroaxonal Dystrophy Rating Scale (INAD-RS) was used for evaluating the severity and progression of INAD patients. Whole-exome sequencing was used to determine the disease's underlying etiology followed by co-segregation analysis using Sanger sequencing. In silico prediction analysis based on the ACMG recommendation was used to assess the pathogenicity of genetic variants. We aimed to survey a genotype-genotype correlation in PLA2G6 considering all reported disease-causing variants in addition to our patients using the HGMD database and the chi-square statistical approach. Results: Eighteen cases of INAD and 7 cases of late-onset PLAN were enrolled. Among 18 patients with INAD, gross motor regression was the most common presenting symptom. Considering the INAD-RS total score, the mean rate of progression was 0.58 points per month of symptoms (Standard error 0.22, lower 95% − 1.10, and upper 95% − 0.15). Sixty percent of the maximum potential loss in the INAD-RS had occurred within 60 months of symptom onset in INAD patients. Among seven adult cases of PLAN, hypokinesia, tremor, ataxic gate, and cognitive impairment were the most frequent clinical features. Various brain imaging abnormalities were also observed in 26 imaging series of these patients with cerebellar atrophy being the most common finding in more than 50%. Twenty unique variants in 25 patients with PLAN were detected including nine novel variants. Altogether, 107 distinct disease-causing variants from 87 patient were analyzed to establish a genotype–phenotype correlation. The P value of the chi-square test did not indicate a significant relationship between age of disease onset and the distribution of reported variants on PLA2G6. Conclusion: PLAN presents with a wide spectrum of clinical symptoms from infancy to adulthood. PLAN should be considered in adult patients with parkinsonism or cognition decline. Based on the current knowledge, it is not possible to foresee the age of disease onset based on the identified genotype. © 2023, The Author(s).
Related Docs
Experts (# of related papers)